Google
×
Advancing Science. Improving Connections. Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal ...
Oct 4, 2023 · In addition, these materials are available at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zynerba's website ...
The Investor Relations website contains information about Harmony Biosciences's business for stockholders, potential investors, and financial analysts.
People also ask
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical ...
Missing: investor relations
Learn how to use EDGAR to research public filings by public companies, mutual funds, ETFs, some annuities, and more. Before you Invest, Investor.gov. Get ...
Aug 14, 2023 · The live and replay webcast of the call will be available on the investor relations page of our website at https://ir.harmonybiosciences.com/.
Aug 14, 2023 · The live and replay webcast of the call will be available on the investor relations page of our website at https://ir.harmonybiosciences.com/.
Investor Relations. NASDAQ: ZYXI. $12.58. $0.23 (1.86%). Currency in USD. Quote ... Sign up to receive updates on the latest investor events, reports, and news ...
Sep 27, 2023 · Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that · Xylophone Acquisition Corp. · Zynerba Pharmaceuticals, Inc.
Sep 27, 2023 · ("Zynerba") (Nasdaq: ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, 2023, unless further extended. The tender offer was ...